Raymond James lowered the firm’s price target on Zura Bio to $17 from $22 and keeps a Strong Buy rating on the shares. The timeline for initial clinical trials that were previously guided for a second half initiation of lead asset tibulizumab are now clarified in systemic sclerosis for the fourth quarter and in hidradenitis suppurativa for the second quarter of 2Q25, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA: